Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Michael R. Bristow: The Consummate Physician-Scientist of This Generation.

Circulation. Heart failure·2026

Same author

Michael R. Bristow, MD, PhD: A Translational Pioneer Who Changed the Field of Heart Failure.

JACC. Basic to translational science·2026

Same author

Michael R. Bristow, MD, PhD: A Translational Pioneer Who Changed the Field of Heart Failure.

JACC. Heart failure·2026

Same author

Neurodivergence in US Medical Education.

JAMA·2026

Same author

Psoas Muscle Index Predicts Perioperative Mortality in Patients Undergoing LVAD Implantation.

Muscles (Basel, Switzerland)·2025

Same author

Evaluating the intersectionality of race and gender and its impact on heart transplant equity, listing outcomes, and allocation policy.

Journal of cardiology·2025

Search research articles

Related Experiment Videos

Pharmacogenetics in heart failure: how it will shape the future.

Eman Hamad¹, Arthur M Feldman

¹Center for Translational Medicine, Department of Medicine, Jefferson Medical College, 1025 Walnut Street, Philadelphia, PA 19107, USA.

Heart Failure Clinics

|December 1, 2009

Summary

Pharmacogenomics research shows genetic variations impact heart failure (HF) occurrence and treatment response. Understanding these genetic factors can personalize HF therapies for better patient outcomes.

Related Experiment Videos

Area of Science:

Pharmacogenomics
Cardiovascular Medicine
Genetics

Background:

Pharmacogenomics investigates genetic influences on drug and device responses.
Heart failure (HF) research highlights the role of genetic variations in disease prediction and treatment efficacy.

Observation:

Clinical trials indicate genetic variations affect HF occurrence in systolic dysfunction patients.
Genetic factors influence the effectiveness of standard HF therapies and patient outcomes.

Findings:

Individual genetic makeup impacts HF risk and response to treatments.
Variations in genes encoding proteins can alter pharmacologic agent effects.

Implications:

Pharmacogenomics offers potential for personalized treatment strategies in HF.
Tailoring therapies based on genetic profiles may improve HF patient management and outcomes.